Mason & Associates Inc Sells 243 Shares of Amgen Inc. (NASDAQ:AMGN)

Mason & Associates Inc decreased its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 10.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,030 shares of the medical research company’s stock after selling 243 shares during the period. Mason & Associates Inc’s holdings in Amgen were worth $529,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. SignalPoint Asset Management LLC raised its stake in Amgen by 10.9% during the 4th quarter. SignalPoint Asset Management LLC now owns 1,358 shares of the medical research company’s stock valued at $354,000 after buying an additional 134 shares during the last quarter. StrongBox Wealth LLC grew its holdings in shares of Amgen by 0.4% in the fourth quarter. StrongBox Wealth LLC now owns 11,649 shares of the medical research company’s stock worth $3,036,000 after acquiring an additional 42 shares during the period. Flywheel Private Wealth LLC purchased a new stake in Amgen during the fourth quarter valued at $340,000. Rovin Capital UT ADV lifted its holdings in Amgen by 89.1% in the fourth quarter. Rovin Capital UT ADV now owns 1,235 shares of the medical research company’s stock valued at $322,000 after acquiring an additional 582 shares during the period. Finally, Smith Thornton Advisors LLC boosted its position in Amgen by 53.3% in the fourth quarter. Smith Thornton Advisors LLC now owns 1,185 shares of the medical research company’s stock worth $309,000 after purchasing an additional 412 shares during the last quarter. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Amgen Stock Performance

Shares of NASDAQ:AMGN opened at $268.94 on Thursday. The firm has a fifty day simple moving average of $277.12 and a two-hundred day simple moving average of $308.03. Amgen Inc. has a 52 week low of $253.30 and a 52 week high of $346.85. The company has a quick ratio of 0.96, a current ratio of 1.32 and a debt-to-equity ratio of 7.55. The stock has a market capitalization of $144.56 billion, a P/E ratio of 34.44, a PEG ratio of 2.68 and a beta of 0.56.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Wednesday, October 30th. The medical research company reported $5.58 EPS for the quarter, topping the consensus estimate of $5.11 by $0.47. Amgen had a return on equity of 168.35% and a net margin of 13.00%. The company had revenue of $8.50 billion during the quarter, compared to analyst estimates of $8.50 billion. During the same quarter last year, the business posted $4.96 earnings per share. The firm’s revenue was up 23.2% on a year-over-year basis. On average, analysts expect that Amgen Inc. will post 19.57 earnings per share for the current fiscal year.

Amgen Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, February 14th will be given a $2.38 dividend. The ex-dividend date of this dividend is Friday, February 14th. This is an increase from Amgen’s previous quarterly dividend of $2.25. This represents a $9.52 dividend on an annualized basis and a yield of 3.54%. Amgen’s dividend payout ratio (DPR) is currently 115.24%.

Analyst Ratings Changes

Several research firms have recently commented on AMGN. Piper Sandler reduced their price target on shares of Amgen from $344.00 to $310.00 and set an “overweight” rating for the company in a research report on Thursday, January 2nd. Wolfe Research assumed coverage on shares of Amgen in a research report on Friday, November 15th. They issued a “peer perform” rating on the stock. Cantor Fitzgerald restated an “overweight” rating and issued a $405.00 price objective on shares of Amgen in a research note on Tuesday, October 22nd. Truist Financial decreased their target price on Amgen from $333.00 to $298.00 and set a “hold” rating on the stock in a report on Wednesday, January 8th. Finally, Jefferies Financial Group restated a “buy” rating and issued a $380.00 price target on shares of Amgen in a research report on Tuesday, November 12th. Two research analysts have rated the stock with a sell rating, twelve have issued a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Amgen currently has an average rating of “Hold” and a consensus target price of $314.91.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.